In the latest trading session, Adma Biologics (ADMA) closed at $8.33, marking a -1.83% move from the previous day. This change lagged the S&P 500's daily gain of 1.75%. Meanwhile, the Dow experienced a rise of 1.86%, and the technology-dominated Nasdaq saw an increase of 2.54%.
The infectious disease drug developer's shares have seen a decrease of 0.24% over the last month, not keeping up with the Medical sector's gain of 3.73% and outstripping the S&P 500's loss of 1.63%.
The investment community will be paying close attention to the earnings performance of Adma Biologics in its upcoming release.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.84 per share and a revenue of $540.09 million, representing changes of +40% and +5.86%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Adma Biologics. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Adma Biologics is currently a Zacks Rank #5 (Strong Sell).
Digging into valuation, Adma Biologics currently has a Forward P/E ratio of 10.1. This expresses a discount compared to the average Forward P/E of 20.9 of its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 153, which puts it in the bottom 38% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADMA Biologics Inc (ADMA): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).